Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 730-737

  Blount, Mitsi A ^a   Zoraghi, Roya ^a   Bessay, Emmanuel P ^a   Beasley, Alfreda ^a   Francis, Sharron H ^a   Corbin, Jackie D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; BINDING AFFINITY; CATALYSIS; DEGRADATION; ENZYME ACTIVITY; KINETICS; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; CARBOLINES; CATALYTIC DOMAIN; CATTLE; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; IMIDAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TRIAZINES; TRITIUM;

EID: 35548957803     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.126540     Document Type: Article

References (38)

1. Artemyev NO and Hamm HE (1992) Two-site high-affinity interaction between inhibitory and catalytic subunits of rod cyclic GMP phosphodiesterase. Biochem J 283:273-279.
2. Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH, and Corbin JD (2007) Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front Biosci 12:1899-1910.
3. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152.
4. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, and Francis SH (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in PDE5 dimerization. Mol Pharmacol 70:1822-1831.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Conti M and Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511.
7. Conti M and Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
8. 3H]Sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63:1364-1372.
9. Corbin JD and Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729-13732.
10. Corbin JD, Turko IV, Beasley A, and Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760-2767.
11. Daugan AC (2000) inventors; ICOS Corporation, assignee. Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence. U.S. Patent 6,140,329. 2000 Oct 31.
12. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, and Corbin JD (2002) Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem 277:47581-47587.
13. Francis SH, Blount MA, Zoraghi R, and Corbin JD (2005) Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Front Biosci 10:2097-2117.
14. Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, and Corbin JD (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14:81-92.
15. Francis SH, Lincoln TM, and Corbin JD (1980) Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255:620-626.
16. Francis SH, Sekhar KR, Rouse AB, Grimes KA, and Corbin JD (2003) Single step isolation of sildenafil from commercially available Viagra tablets. Int J Impot Res 15:369-372.
17. Francis SH, Turko IV, and Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
18. Gupta M, Kovar A, and Meibohm B (2005) The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987-1003.
19. Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
20. Laliberté F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, et al. (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39:6449-6458.
21. McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK, Seger D, Turko IV, Beavo JA, Francis SH, and Corbin JD (1995) An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem 270:30671-30679.
22. Moncada I, Jara J, Subira D, Castano I, and Hernandez C (2004) Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46:357-360; discussion 360-351.
23. Monod J, Wyman J, and Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88-118.
24. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, and Koesling D (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160:719-727.
25. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, and Friebe A (2001) Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155:271-278.
26. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, et al. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 36:14250-14261.
27. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469-478.
28. Schneider HH, Schmiechen R, Brezinski M, and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
29. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
30. Stroop SD and Beavo JA (1991) Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem 266:23802-23809.
31. Terry R, Cheung YF, Praestegaard M, Baillie GS, Huston E, Gall I, Adams DR, and Houslay MD (2003) Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell Signal 15:955-971.
32. Thomas MK, Francis SH, Beebe SJ, Gettys TW, and Corbin JD (1992) Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. Adv Second Messenger Phosphoprotein Res 25:45-53.
33. Thomas MK, Francis SH, and Corbin JD (1990a) Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem 265:14964-14970.
34. Thomas MK, Francis SH, and Corbin JD (1990b) Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265:14971-14978.
35. Valiquette L, Montorsi F, Hellstrom WJ, Giuliano F, Homering M, Taylor T, and Eardley I (2005) Penetration and maintenance of erection with vardenafil: a time-from-dosing analysis. Can J Urol 12:2687-2698; discussion 2699.
36. Wyatt TA, Naftilan AJ, Francis SH, and Corbin JD (1998) ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274:H448-H455.
37. Zhao Y, Zhang HT, and O'Donnell JM (2003) Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307:246-253.
38. Zoraghi R, Bessay EP, Corbin JD, and Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051-12063.